Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________________ FORM 10-Q ________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 ...

Exhibit 99.1 Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update • Cemacabtagene Ansegedleucel (Cema-Cel) ◦ Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom, Reinforcing Company’s Conviction in the Unique Opportunity in Large B Cell Lymphoma (LBCL) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) ▪ Extended Territory Rights Substantially Increase Market Opportunity in 1L Consolidation LBCL and R/R CLL From More Than $6 Bi ...

Cemacabtagene Ansegedleucel (Cema-Cel) Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom, Reinforcing Company's Conviction in the Unique Opportunity in Large B Cell Lymphoma (LBCL) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Extended Territory Rights Substantially Increase Market Opportunity in 1L Consolidation LBCL and R/R CLL From More Than $6 Billion in the US to More Than $9.5 Billion in the Combined U.S., EU Member States and the United KingdomCon ...

Conference Call and Webcast Scheduled for May 13, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report first quarter 2024 financial results and provide a business update on May 13, 2024, after the close of the market. The announcement will be foll ...

$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential of Dagger® Technology to Optimize CAR T Cell Expansion and Persistence SOUTH SAN FRANCISCO, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer ...

Investing in the technologies of tomorrow can be a lucrative investment strategy. If investors can discern trends as they develop, they can stay ahead of the curve and reap the rewards. This is what made Cathie Wood and her firm ARK Invest famous. Her funds invest in companies she "expect[s] to be the leaders, enablers, and beneficiaries of disruptive innovation."Wood's big bets have won her a lot of fans, but it hasn't always been a smooth ride. Investing in the cutting-edge means investing in what is larg ...

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four investor conferences in the second quarter of 2024. Canaccord Genuity Horizons in Oncology Virtual ConferenceMonday, April 15, 202412:00pm PT/3:00pm ET JPM Securities Life Sciences Conference Tuesday, May 14, 2024 ...

Financial Performance - Allogene Therapeutics, Inc. reported an adjusted loss of 43 cents per share in Q4 2023, which was better than the Zacks Consensus Estimate of a loss of 47 cents [1] - Including impairment charges, the company posted a loss of 51 cents in Q4, compared to a loss of 67 cents in the same quarter last year [2] - Revenues for the quarter were $0.02 million, missing the Zacks Consensus Estimate of $0.05 million, and down 19% year over year [2] - For the full year 2023, Allogene recorded total revenues of $0.1 million, a decrease of 39% year over year, and reported a loss of $2.09 per share, which was narrower than the previous year's loss of $2.38 [4] Expense Management - Research and development (R&D) expenses were $54.7 million, down 28% from the year-ago quarter [3] - General and administrative (G&A) expenses declined 18% year over year to $17.2 million [3] - The company anticipates operating expenses for 2024 to be around $280 million, including nearly $60 million in non-cash stock-based compensation [5] Cash Position and Market Reaction - As of December 31, 2023, Allogene had $448.7 million in cash, cash equivalents, and investments, down from $497.7 million as of September 30, 2023 [3] - Following the earnings announcement, shares of Allogene rose 5% in after-market trading on March 14, attributed to lower-than-expected operating expenses and cash burn [5] - Year to date, the stock has surged 40%, outperforming the industry growth of 0.8% [5] Pipeline Developments - In January, Allogene announced it would deprioritize two pivotal mid-stage studies, ALPHA2 and EXPAND, focusing instead on developing cema-cel as a frontline treatment for LBCL [6][7] - The company initiated start-up activities for the phase II ALPHA3 study, expected to begin in mid-2024, evaluating cema-cel for newly diagnosed LBCL patients [7] - Allogene is also exploring allogenic CAR-T cell therapies for autoimmune diseases, partnering with Arbor Biotechnologies to utilize CRISPR technology for a new candidate, ALLO-329, targeting lupus/SLE [8]

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript March 14, 2024 5:00 PM ET Company Participants Christine Cassiano - Chief Corporate Affairs and Brand Strategy Officer David Chang - President and Chief Executive Officer Zachary Roberts - Executive Vice President of Research and Development and Chief Medical Officer Geoff Parker - Chief financial officer Conference Call Participants Tyler Van Buren - TD Cowen Salveen Richter - Goldman Sachs Brian Cheng - JPMorgan Jack Allen - Baird ...

Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.51%. A quarter ago, it was expected that this immuno-oncology company would post a loss of $0.53 per share when it actually produced a loss of $0.37, delivering a surprise of 30.19%.Over the last four quarters, the ...